Design of stock acquisition rights whose exercise conditions combine China approval of F351, China local-currency sales in the pharmaceutical business, and U.S.-dollar sales in the medtech business. The distinguishing feature is that regulatory approval and region-specific sales across multiple businesses are made conditions simultaneously.